BL
AZN icon

Balentine LLC’s AstraZeneca AZN Stock Holding History

Balentine LLC’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,408
Closed -$1.27M – 216
2024
Q1 		$1.27M Buy
9,408
+2,662
+39% +$352K 0.04% 153
2023
Q4 		$909K Buy
6,746
+4,310
+177% +$560K 0.03% 185
2023
Q3 		$330K Sell
2,436
-128
-5% -$17.5K 0.01% 347
2023
Q2 		$367K Buy
2,564
+132
+5% +$19.4K 0.01% 340
2023
Q1 		$338K Buy
2,432
+13
+0.5% +$1.75K 0.01% 378
2022
Q4 		$328K Sell
2,419
-446
-16% -$55.9K 0.01% 427
2022
Q3 		$314K Sell
2,865
-1,368
-32% -$174K 0.01% 382
2022
Q2 		$559K Sell
4,233
-2,299
-35% -$302K 0.02% 287
2022
Q1 		$867K Buy
6,532
+2,899
+80% +$348K 0.03% 195
2021
Q4 		$423K Buy
3,633
+676
+23% +$79.5K 0.01% 193
2021
Q3 		$355K Sell
2,957
-112
-4% -$13K 0.01% 159
2021
Q2 		$368K Buy
+3,069
New +$337K 0.01% 100
2020
Q3 		– Sell
-1,026
Closed -$108K – 206
2020
Q2 		$108K Buy
+1,026
New +$106K 0.01% 142
2019
Q4 		– Sell
-666
Closed -$59K – 611
2019
Q3 		$59K Hold
666
– – ﹤0.01% 121
2019
Q2 		$55K Buy
666
+85
+15% +$6.67K ﹤0.01% 101
2019
Q1 		$47K Buy
581
+257
+79% +$20.3K ﹤0.01% 125
2018
Q4 		$25K Hold
324
– – ﹤0.01% 168
2018
Q3 		$26K Buy
324
+84
+35% +$6.35K ﹤0.01% 114
2018
Q2 		$17K Buy
+240
New +$17.3K ﹤0.01% 72
2018
Q1 		– Sell
-744
Closed -$52K – 99
2017
Q4 		$52K Sell
744
-18
-2% -$1.21K ﹤0.01% 270
2017
Q3 		$52K Buy
+762
New +$48.1K ﹤0.01% 256

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balentine LLC's AZN Position: Q2 2024 in Review

Balentine LLC sold out of AstraZeneca (AZN) in Q2 2024, closing a stake of 9,408 shares — an estimated $1.27M sold.

Balentine LLC first reported a position in AZN in Q3 2017 and held it in 21 quarters. The position peaked at $1.27M in Q1 2024. 1,212 funds tracked by Wall St. Rank hold AZN as of Q2 2024.

  • Balentine LLC reported no remaining AstraZeneca position as of Q2 2024 after selling out during the quarter.
  • Balentine LLC sold 9,408 AstraZeneca shares in Q2 2024, an estimated $1.27M.
  • Balentine LLC first reported a position in AstraZeneca in Q3 2017 and held it in 21 quarters.
  • Balentine LLC's AstraZeneca position peaked at $1.27M in Q1 2024.
  • 1,212 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2024.

Based on Balentine LLC's 13F filing for Q2 2024, filed 7 Aug 2024.